Amgen Inc. $AMGN Shares Sold by Keybank National Association OH

Keybank National Association OH reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 1.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 181,556 shares of the medical research company’s stock after selling 2,027 shares during the quarter. Keybank National Association OH’s holdings in Amgen were worth $51,235,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of AMGN. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the second quarter valued at $27,000. Evelyn Partners Investment Management LLP purchased a new position in Amgen in the 2nd quarter worth $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen during the 2nd quarter worth about $32,000. Quaker Wealth Management LLC grew its stake in Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares during the last quarter. Finally, Cloud Capital Management LLC acquired a new position in shares of Amgen in the third quarter valued at about $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AMGN. Deutsche Bank Aktiengesellschaft lifted their target price on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Truist Financial upped their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. UBS Group raised their target price on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a report on Monday. Finally, Cantor Fitzgerald boosted their target price on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $342.45.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last three months. 0.76% of the stock is currently owned by company insiders.

Amgen Stock Down 0.3%

AMGN stock opened at $341.88 on Friday. Amgen Inc. has a one year low of $261.43 and a one year high of $353.25. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The firm’s fifty day moving average is $332.60 and its 200 day moving average is $309.22. The firm has a market cap of $184.10 billion, a PE ratio of 26.42, a P/E/G ratio of 3.02 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period in the prior year, the company posted $5.58 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.